期刊
MICROBIOLOGY SPECTRUM
卷 10, 期 3, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/spectrum.01538-22
关键词
cross-protection; pandemic preparedness; neutralizing antibodies; low-cost vaccine platform; multivalent vaccine
类别
资金
- NIAID [HHSN272201400008C, R21AI157606, 75N93021C00014]
- NIH [R01 DK130425/DK/NIDDK]
- Pfizer
- Senhwa Biosciences
- Kenall Manufacturing
- Avimex
- Johnson Johnson
- Dynavax
- 7Hills Pharma
- Pharmamar
- ImmunityBio
- Accurius
- Hexamer
- N-fold LLC
- Model Medicines
- Atea Pharma
- Merck
- Nanocomposix
This paper describes an extended work on the Newcastle disease virus (NDV)-based vaccine focusing on multivalent formulations of NDV vectors expressing different prefusion-stabilized versions of the spike proteins of different SARS-CoV-2 variants of concern (VOC). It demonstrates that this low-cost NDV platform can be easily adapted to construct vaccines against SARS-CoV-2 variants. Importantly, the trivalent preparation (composed of the ancestral Wuhan, Beta, and Delta vaccines) substantially increases the levels of protection and of cross-neutralizing antibodies against mismatched, phylogenetically distant variants (including the currently circulating Omicron variant). These findings will help guide efforts for pandemic preparedness against new variants in the future.
Equitable access to vaccines is necessary to limit the global impact of the coronavirus disease 2019 (COVID-19) pandemic and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. In previous studies, we described the development of a low-cost vaccine based on a Newcastle Disease virus (NDV) expressing the prefusion-stabilized spike protein from SARS-CoV-2, named NDV-HXP-S. Here, we present the development of next-generation NDV-HXP-S variant vaccines, which express the stabilized spike protein of the Beta, Gamma, and Delta variants of concerns (VOC). Combinations of variant vaccines in bivalent, trivalent, and tetravalent formulations were tested for immunogenicity and protection in mice. We show that the trivalent preparation, composed of the ancestral Wuhan, Beta, and Delta vaccines, substantially increases the levels of protection and of cross-neutralizing antibodies against mismatched, phylogenetically distant variants, including the currently circulating Omicron variant. IMPORTANCE This manuscript describes an extended work on the Newcastle disease virus (NDV)-based vaccine focusing on multivalent formulations of NDV vectors expressing different prefusion-stabilized versions of the spike proteins of different SARS-CoV-2 variants of concern (VOC). We demonstrate here that this low-cost NDV platform can be easily adapted to construct vaccines against SARS-CoV-2 variants. Importantly, we show that the trivalent preparation, composed of the ancestral Wuhan, Beta, and Delta vaccines, substantially increases the levels of protection and of cross-neutralizing antibodies against mismatched, phylogenetically distant variants, including the currently circulating Omicron variant. We believe that these findings will help to guide efforts for pandemic preparedness against new variants in the future. This manuscript describes an extended work on the Newcastle disease virus (NDV)-based vaccine focusing on multivalent formulations of NDV vectors expressing different prefusion-stabilized versions of the spike proteins of different SARS-CoV-2 variants of concern (VOC). We demonstrate here that this low-cost NDV platform can be easily adapted to construct vaccines against SARS-CoV-2 variants.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据